Latest news with #TAR-200
Yahoo
29-04-2025
- Health
- Yahoo
New data from J&J's bladder cancer drug-device trial strengthens support for NDA
Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Data, announced during the Paradigm-Shifting, Practice-Changing Clinical Trials in Urology plenary session at the American Urological Association (AUA) Annual Meeting 2025, showed a high response rate in one of the cohorts from the Phase IIb SunRISe-1 trial (NCT04640623). J&J announced new data from both cohort two and cohort four at the conference. TAR-200, trademarked as GemRIS, is a drug-device combination product that continuously delivers gemcitabine chemotherapy directly to the bladder over a week. It can be inserted without the need for anaesthesia or sedation. J&J acquired TAR-200 and the drug delivery technology during its purchase of Taris Biomedical in 2019. In the new data from cohort two, which enrolled 85 BCG-unresponsive NMIBC patients with carcinoma in situ, 82.4% achieved a complete response (CR), with this translating into sustained disease control, with 52.9% of responders maintaining CR at one year. In the same cohort, the median duration of response (DOR) was 25.8 months and at 12 months, 86.6% of patients who responded to treatment remained cystectomy-free. Meanwhile, patients in cohort four, 52 HR-NMIBC patients with papillary disease-only, 85.3% and 81.1% disease-free survival (DFS) rates at six and nine months. Also, 94.2% of patients avoided cystectomy at a median follow-up of 12.8 months. J&J also reported progression-free (PFS) and overall survival (OS) rates of 95.6% and 98% at nine months, respectively. In both cohorts, TAR-200, the treatment was well-tolerated, with most adverse events (AEs) being mild urinary symptoms. These findings indicate that TAR-200 offers a highly effective and durable treatment option for patients with certain types of BCG-unresponsive HR-NMIBC. Most treatment-related AEs were mild and manageable. Between both cohorts, seven patients discontinued treatment due to treatment-related AEs, and there were no treatment-related deaths. Disease area leader of bladder cancer for J&J Innovative Medicine, Dr. Christopher Cutie, said: 'Bladder cancer is one of the ten most common cancers worldwide, yet treatment options have remained largely unchanged for over 40 years, leaving patients with few choices if initial BCG therapy does not work. TAR-200 is designed to allow for sustained delivery of medication directly into the bladder through a brief and routine procedure, which benefits patients. These data now show patients can remain cancer-free for a meaningful period of time, marking a significant step forward for those facing this challenging disease.' The new data, announced on Saturday 26 April comes after J&J filed a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for TAR-200 in January 2025 based on previous data announced from the SunRISe-1 trial. The application is for the use of TAR-200 in NMIBC patients with carcinoma in situ who are BCG-unresponsive, with or without papillary tumours. This submission is being reviewed through the Real-Time Oncology Review (RTOR) programme, which allows the FDA to review data before the complete application is formally submitted. Earlier results from cohort two were presented at the European Society of Medical Oncology (ESMO) Congress 2024 and the AUA 2024 Meeting. TAR-200 did not, however, show benefit in a Phase III trial in patients with muscle-invasive bladder cancer (MIBC) not undergoing radical cystectomy. The Phase III SunRISe-2 study (NCT04658862) was terminated by J&J after an independent data monitoring committee said the trial was unlikely to meet its primary endpoint of bladder intact-event free survival (BI-EFS). The Phase II SunRISe-4 trial, also in patients with MIBC, is ongoing. The SunRISe-1 trial is ongoing, and TAR-200 is also being investigated in NMIBC in two Phase III studies, SunRISe-3 (NCT05714202) and SunRISe-5 (NCT06211764). Also at the AUA Annual Meeting 2025, Pfizer presented positive data from a Phase III trial of sasanlimab and BCG, with the combination therapy improving event-free survival (EFS) in BCG-naïve high-risk NMIBC patients compared to subjects who were only given BCG, meeting the trial's primary endpoint. "New data from J&J's bladder cancer drug-device trial strengthens support for NDA" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Insider
28-04-2025
- Business
- Business Insider
Johnson & Johnson announces new data from Cohort 2 of Phase 2b SunRISe-1
Johnson & Johnson announced new data from Cohort 2 of the pivotal Phase 2b SunRISe-1 study evaluating TAR-200-an intravesical gemcitabine releasing system-for patients with certain types of bladder cancer. The findings demonstrate the highest complete response rate without reinduction with more than half of responders remaining cancer-free for at least 12 months. These results highlight the potential of TAR-200 as a breakthrough for people with Bacillus Calmette-Guerin-unresponsive, high-risk non-muscle-invasive bladder cancer, HR-NMIBC, with carcinoma in situ, CIS, with or without papillary tumors who are ineligible or refuse radical cystectomy. As of March 2025, 82.4 percent of the 85 enrolled patients in the study achieved a complete response, meaning their cancer was undetectable following treatment. This high response rate translated into sustained disease control, with 52.9 percent of responders maintaining complete response at one year. The median duration of response was 25.8 months, indicating that many patients remained cancer-free for over two years without the need for reinduction therapy. At 12 months, 86.6 percent of responders remained cystectomy-free. Importantly, the treatment was well-tolerated, with most adverse events being mild urinary symptoms. These findings show that TAR-200 offers a highly effective and durable treatment option for patients with certain types of BCG-unresponsive HR-NMIBC. Stay Ahead of the Market:
Associated Press
21-04-2025
- Health
- Associated Press
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2) Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer RARITAN, N.J., April 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26-29 in Las Vegas. Among the highlights are the 12-month duration of response (DOR) data from the Phase 2b Cohort 2 SunRISe-1 study, evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with Bacillus Calmette-Guérin (BCG)—unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS) with or without papillary disease. These findings will be featured in the Practice-changing, Paradigm-shifting Clinical Trials in Urology plenary session on Saturday, April 26. Bladder cancer ranks among the top ten most common cancers worldwide, affecting nearly a million people each year.1 Despite advancements, standard treatment has remained largely unchanged for over 40 years, leaving patients with limited treatment options if initial BCG therapy does not work.2 TAR-200 delivers sustained medication directly into the bladder and, in a pre-clinical setting, has been shown to allow for depth of penetration across bladder tissue layers.3 'Patients with bladder cancer need more effective treatment options that are both tolerable and easily incorporated into everyday practice, especially for those with HR-NMIBC, a highly recurrent disease that often necessitates difficult, life-altering decisions like bladder removal,' said Yusri Elsayed, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. 'TAR-200 provides a new approach, with clinical data showing an impressive complete response rate, meaning the cancer was undetectable following treatment. The highly anticipated 12-month duration of response findings from our Cohort 2, SunRISe-1 study further support the potential for patients to remain cancer-free for a clinically meaningful period.' A second plenary presentation will feature first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200 monotherapy in patients with BCG–unresponsive, papillary-only HR-NMIBC. In this patient population, bladder removal remains a standard treatment, but many patients are elderly, have significant comorbidities, or are unwilling to undergo radical surgery, making treatment challenging.4 'Patients deserve more than the currently available treatment options. TAR-200 is a groundbreaking therapy for early-stage bladder cancer, designed to deliver a sustained local release of medication directly into the bladder—right where it is needed,' said Biljana Naumovic, U.S. President, Oncology, Solid Tumor, Johnson & Johnson Innovative Medicine. 'This innovation provides a bladder-sparing treatment option that can meaningfully improve outcomes while integrating seamlessly into any urology practice.' TAR-200 is inserted directly into the bladder by a healthcare professional in a brief outpatient, in-office procedure, without the need for anesthesia. Designed to remain in the bladder, it does not interfere with daily activities and provides sustained release of medication throughout the day. To date, TAR-200 has been placed more than 10,000 times as part of the SunRISe clinical program. AUA 2025 Presentation Highlights: A complete list of Johnson & Johnson's sponsored abstracts is available on About TAR-200 TAR-200 is an investigational intravesical gemcitabine releasing system. In January 2025, Johnson & Johnson announced the initiation of a new drug application with the FDA for TAR-200 under the real-time oncology review (RTOR) program. In December 2023, the FDA granted Breakthrough Therapy Designation (BTD) to TAR-200 for the treatment of adult patients with BCG—unresponsive HR-NMIBC with CIS who are ineligible for or have elected not to undergo radical cystectomy. The safety and efficacy of TAR-200 are being evaluated in Phase 2 and Phase 3 studies in patients with MIBC in SunRISe-4, and NMIBC in SunRISe-1, SunRISe-3 and SunRISe-5. About TAR-210 TAR-210 is an investigational intravesical erdafitinib releasing system. The safety and efficacy of TAR-210 is being evaluated in a Phase 1 study ( NCT05316155 ) in patients with muscle-invasive bladder cancer (MIBC) and NMIBC. About High-Risk Non-Muscle-Invasive Bladder Cancer High-risk non-muscle-invasive bladder cancer is a type of non-invasive bladder cancer that is more likely to recur or spread beyond the lining of the bladder, called the urothelium, and progress to invasive bladder cancer compared to low-risk NMIBC.5,6 HR-NMIBC makes up 15-44 percent of patients with NMIBC and is characterized by a high-grade, large tumor size, presence of multiple tumors, with or without CIS.7 Radical cystectomy is currently recommended for NMIBC patients who fail BCG therapy, with over 90 percent cancer-specific survival if performed before muscle-invasive progression.8,9 Given that NMIBC typically affects older patients, many may be unwilling or unfit to undergo radical cystectomy.10 The high rates of recurrence and progression can pose significant morbidity and distress for these patients.3,6 About Prostate Cancer Approximately 300,000 people are diagnosed with prostate cancer each year in the U.S.11 Up to 40 percent of patients will be classified as high-risk.12 Despite advancements in treatment, disease recurrence remains substantial; up to 50 percent of patients within ten years of surgery experience recurrence and carry a significant risk of disease progression and death.13 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of TAR-200, TAR-210 or BALVERSA® (erdafitinib). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC, Janssen Scientific Affairs, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC, Janssen Scientific Affairs, LLC nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments. 1 2 Dobruch J, Oszczudłowski M. Bladder Cancer: Current Challenges and Future Directions. Medicina (Kaunas). 2021;57(8):749. Published 2021 Jul 24. doi:10.3390/medicina57080749 3 Pradère B., et al. PENELOPE: Tissue penetration of gemcitabine phosphate metabolites following TAR-200 administration versus standard intravesical instillation in minipigs. EAU 2025. March 23, 2025. 4 Lebacle C, Loriot Y, Irani J. BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?. World J Urol. 2021;39(11):4037-4046. doi:10.1007/s00345-021-03666-w 5 Grab-Heyne K, Henne C, Mariappan P, et al. Intermediate and high-risk non–muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023;13:1170124. 6 Lieblich A, Henne C, Mariappan P, Geiges G, Pöhlmann J, Pollock RF. The management of non–muscle-invasive bladder cancer: a comparison of European and UK guidelines. J Clin Urol. 2018;11(2):144-148. 7 Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75-94. doi:10.1016/ 8 Brooks NA, O'Donnell MA. Treatment options in non–muscle-invasive bladder cancer after BCG failure. Indian J Urol. 2015;31(4):312-319. doi:10.4103/0970-1591.166475 9 Guancial EA, Roussel B, Bergsma DP, et al. Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging. 2015;10:939-949. 10 Chamie K, Litwin MS, Bassett JC, et al. Recurrence of high-risk bladder cancer: A population-based analysis. Cancer. 2013;119(17):3219-3227. 11 Key statistics for prostate cancer. American Cancer Society. Accessed September 2024. 12 Cooperberg MR, Cowan J, Broering JM, et al. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008;26(3):211-218. doi: 10.1007/s00345-008-0250-7. 13 Napodano G, Ferro M, Sanseverino R. High-risk prostate cancer: A very challenging disease in the field of uro-oncology. Diagnostics (Basel). 2021;11(3):400. doi: 10.3390/diagnostics11030400. View original content to download multimedia: SOURCE Johnson & Johnson
Globe and Mail
26-03-2025
- Business
- Globe and Mail
Bladder Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Bladder Cancer Pipeline Insight 2025' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Bladder Cancer Research. Learn more about our innovative pipeline today! @ Bladder Cancer Pipeline Outlook Key Takeaways from the Bladder Cancer Pipeline Report In March 2025, Janssen Research & Development LLC announced a phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy. In March 2025, Fidia Farmaceutici announced a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unwilling or unfit to undergo radical cystectomy. In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive and cancer free longer than those who receive placebo and pembrolizumab, and to learn about the safety of V940, pembrolizumab, and EV, and if people tolerate them. DelveInsight's Bladder Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment. The leading Bladder Cancer Companies such as UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others. Promising Bladder Cancer Therapies such as Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others. Stay informed about the cutting-edge advancements in Bladder Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Bladder Cancer Clinical Trials Assessment Bladder cancer Emerging Drugs Profile UGN-102: UroGen Pharma Ltd. UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin. It is been developed by utilizing UroGen's proprietary RTGel® technology which is a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting. Currently it is in Phase III stage of clinical trial for the treatment of Bladder Cancer. APL 1202 : Asieris Pharmaceuticals APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment. It is currently in registration clinical trials in China, either as single agent as first-line treatment for patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC), or in combination with a chemotherapy as second-line treatment in patients with intermediate and high-risk chemo-refractory NMIBC. Currently, the drug is being evaluated in the Phase III stage for Bladder Cancer. Trilaciclib: G1 Therapeutics, Inc. Trilaciclib, is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. It is a transient IV-administered CDK4/6 inhibitor, a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. Currently the drug is being evaluated in Phase II for the treatment of Bladder Cancer. Catumaxomab: LintonPharm Co.,Ltd. Catumaxomab is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. The drug kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. The drug is in Phase I/II stage of clinical trials for the treatment of bladder cancer. VAX 014: Vaxiion Therapeutics VAX014 is a novel rBMC-based oncolytic immunotherapy. VAX014is a first-in-class tumor-targeted oncolytic agent based on Vaxiion's proprietary rBMC technology. It works by specifically targeting and delivering a novel fast-acting pre-formed oncolytic protein toxin directly to tumor cells that express either α3β1 or α5β1 integrin(s), both commonly found to be selectively expressed in many solid tumor types. The drug is in Phase I stage of clinical trials for the treatment of bladder cancer. Learn more about Bladder Cancer Drugs opportunities in our groundbreaking Bladder Cancer Research and development projects @ Bladder Cancer Unmet Needs Bladder Cancer Companies UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others. Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Oral Parenteral Intravenous Subcutaneous Topical Bladder Cancer Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Discover the latest advancements in Bladder Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Bladder Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Bladder Cancer Pipeline Report Coverage- Global Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Bladder Cancer Companies- UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others Bladder Cancer Therapies- Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others. For a detailed overview of our latest research findings and future plans, read the full details of Bladder Cancer Pipeline on our website @ Bladder Cancer Drugs and Companies Table of Content Introduction Bladder Cancer Executive Summary Bladder Cancer: Overview Bladder Cancer Pipeline Therapeutics Bladder Cancer Pipeline Therapeutic Assessment Late Stage Products (Phase III) UGN-102: UroGen Pharma Ltd. Drug profiles in the detailed report….. Mid Stage Products (Phase II) Trilaciclib: G1 Therapeutics, Inc. Early Stage Products (Phase I) VAX 014: Vaxiion Therapeutics Inactive Products Bladder Cancer Key Companies Bladder Cancer Key Products Bladder Cancer - Unmet Needs Bladder Cancer - Market Drivers and Barriers Bladder Cancer - Future Perspectives and Conclusion Bladder Cancer Analyst Views Bladder Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
